P
Profex
Profex is an international dermatology company, distributing dermatological drugs to Chinese dermatologists, patients and consumers
About Profex
Established in 2001, Profex is a specialty healthcare company headquartered in Shanghai, China, that has carved out a specific niche within the Chinese healthcare market. The firm operates as a strategic partner for multinational pharmaceutical and healthcare companies, focusing on the commercialization of their products within mainland China. This business model centers on scouting, licensing, acquiring, and marketing established global products for the local market, making Profex a crucial gateway for international firms.
The company's primary focus is on skin health and medical aesthetics, offering products for skin treatment, dermo-cosmetics, and hair loss. Over the years, Profex has expanded its portfolio to include other therapeutic areas such as orthopedics, pain management, wound healing, and central nervous system (CNS) treatments. A significant milestone in this expansion was in August 2017, when Xi'an Janssen granted Profex the promotion and distribution rights for two of its main analgesic products in mainland China. This demonstrates the company's strategy of partnering with major global players to broaden its market presence.
The company's services provide dermatologists and other medical professionals with a range of specialized products. In August 2008, Profex secured $15.5 million in a Series A funding round. This investment was co-led by Trident Capital and its Chinese affiliate, The Mustang Group, signaling investor confidence in the company's growth model and its position in the Chinese dermatology market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Huangpu, China
- Employees
- 253
- Open positions
- None listed
- Dealroom signal
- 33.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Health Diagnostics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2008 | $16M | $62M | Trident Capital · Mustang Ventures | — |
Growth signals
Latest recorded traffic for Profex is 440 monthly website visits, down 89.5% over the last three months. Profex's team grew 0.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Trident Capital- MVMustang Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Profex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Profex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





